Cargando…

Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine

We report a case of a 52-year-old female with Large Vessel Vasculitis (LVV) after vaccination with Oxford-AstraZeneca COVID-19 vaccine. She was presented with fever, started two weeks after the second dose of vaccine. Laboratory values, revealed elevated inflammatory markers and chronic disease anae...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katsouli, Olga K., Lainis, Vasileios G., Kapellos, Gerasimos G., Vlachoyiannopoulos, Panayiotis G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201099/ https://www.ncbi.nlm.nih.gov/pubmed/37223596 http://dx.doi.org/10.31138/mjr.34.1.97

Ejemplares similares

Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine
por: Alhammad, Norah S, et al.
Publicado: (2022)

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
por: Østergaard, Søren Dinesen, et al.
Publicado: (2021)

Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
por: Cross, Samuel, et al.
Publicado: (2021)

Et de trois : l’UE recommande le vaccin AstraZeneca/Oxford
por: Manus, Jean-Marie
Publicado: (2021)

Le vaccin AstraZeneca-Oxford sur le bureau de l’EMA
por: Manus, Jean-Marie
Publicado: (2021)

Monoarthritis induced by the Oxford-AstraZeneca(R) SARS-CoV-2 vaccine
por: Schoenardie, Bruna Ossanai, et al.
Publicado: (2022)

Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers
por: Chau, Nguyen Van Vinh, et al.
Publicado: (2022)

Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia
por: Garnier, Matthieu, et al.
Publicado: (2021)

COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine
Publicado: (2021)

COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine
Publicado: (2021)

Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination
por: Permezel, Fiona, et al.
Publicado: (2021)

Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two
por: Razzaq, Azhar Kareem, et al.
Publicado: (2021)

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine
por: Al‐Ahmad, Mona, et al.
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign
por: Vallée, A., et al.
Publicado: (2021)

Granulomatous vasculitis after the AstraZeneca anti–SARS-CoV-2 vaccine
por: Gillion, Valentine, et al.
Publicado: (2021)

ANCA-associated vasculitis following Oxford-AstraZeneca COVID-19 vaccine in Brazil: Is there a causal relationship? A case report
por: Zamoner, Welder, et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021)

Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

AstraZeneca COVID-19 vaccine-related thromboembolism
Publicado: (2021)

Bleeding and clotting with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
por: Agharbi, F.-Z., et al.
Publicado: (2022)

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
por: Hung, Ivan F N, et al.
Publicado: (2021)

Side Effects Following Administration of the First Dose of Oxford-AstraZeneca’s Covishield Vaccine in Bangladesh: A Cross-Sectional Study
por: Jahan, Nishat, et al.
Publicado: (2021)

Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature
por: Alrawashdeh, Hamzeh M, et al.
Publicado: (2022)

A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report
por: Williams, Samuel B. M., et al.
Publicado: (2023)

A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
por: Villa, Miguel, et al.
Publicado: (2021)

Chronic Spontaneous Urticaria Triggered by the AstraZeneca/Oxford COVID-19 Vaccine with Achieved Remission: A Case Report
por: Brooks, Stephanie G, et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine: no increased rate of VTE
Publicado: (2021)

No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Publicado: (2021)

AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
Publicado: (2021)

Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Publicado: (2021)

AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
Publicado: (2021)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
Publicado: (2021)

Ischemic stroke after AstraZeneca (Covid-19) vaccination
por: Alammar, Muath A.
Publicado: (2021)

Lipschütz ulcers after AstraZeneca COVID-19 vaccination()
por: Bracho-Borro, Maria, et al.
Publicado: (2023)

Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen
por: Soltani Hekmat, Ava, et al.
Publicado: (2021)

Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
por: Teh, Natalie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bgnu4ad91tp7ptq8o57am4ibqb